Hetero Ring Patents (Class 544/198)
  • Patent number: 10385076
    Abstract: A surface treatment agent including a compound (?) is provided. The compound (?) has one or more M-OH groups and/or groups capable of forming M-OH (wherein M represents a metal atom), an amino group and a triazine ring; wherein said amino group is bonded to a terminal; one or more said amino groups bonded to the terminal are present; and one or more said triazine rings are present.
    Type: Grant
    Filed: August 8, 2017
    Date of Patent: August 20, 2019
    Assignees: Sulfur Chemical Laboratory, Inc., Meiko Electronics Co., Ltd.
    Inventors: Kunio Mori, Yusuke Matsuno, Katsuhito Mori, Takahiro Kudo, Shuukichi Takii, Shigeru Michiwaki, Manabu Miyawaki, Masanori Yanai, Kouichi Kamiyama, Hitomi Chiba, Yasuyuki Masuda
  • Patent number: 10160736
    Abstract: The present invention relates to synthetic methods for 1,3,4-oxadiazole and 1,3,4-thiadiazole compounds. The general synthetic scheme is: R1 substituents are —CH2OH, —CH(CH3)OH, —CH2Ph, —CH3, or —CH2C(O)NH2 optionally substituted with alkyl or aralkyl. R3 substituents are —CH2OH, —CH3, —CH2CH2C(O)OH, —CH2CH2C(O)NH2, —CH2C(O)NH2, or —CH2C(O)OH, wherein the carboxylic acids and amides are optionally substituted with alkyl or aralkyl.
    Type: Grant
    Filed: October 2, 2017
    Date of Patent: December 25, 2018
    Assignee: Aurigene Discovery Technologies Limited
    Inventors: Pottayil Govindan Nair Sasikumar, Muralidhara Ramachandra, Seetharamaiah Setty Sudarshan Naremaddepalli
  • Patent number: 9833768
    Abstract: Disclosed herein are methods and compositions for purifying proteins from crude solutions.
    Type: Grant
    Filed: July 27, 2017
    Date of Patent: December 5, 2017
    Assignees: Impossible Foods Inc., The Board of Trustees of the Leland Stanford Junior University
    Inventors: Patrick O'Reilly Brown, R. Edward Watts, Pehr Harbury
  • Patent number: 9776978
    Abstract: The present invention relates to 1,3,4-oxadiazole and 1,3,4-thiadiazole compounds as therapeutic agents capable of inhibiting the programmed cell death 1 (PD1) signalling pathway. The invention also refers to derivatives of the therapeutic agents. The invention also encompasses the use of the said therapeutic agents and derivatives for treatment of disorders via immunopotentiation comprising inhibition of immunosuppressive signal induced due to PD-1, PD-L1, or PD-L2 and therapies using them.
    Type: Grant
    Filed: October 18, 2016
    Date of Patent: October 3, 2017
    Assignee: Aurigene Discovery Technologies Limited
    Inventors: Pottayil Govindan Nair Sasikumar, Muralidhara Ramachandra, Seetharamaiah Setty Sudarshan Naremaddepalli
  • Patent number: 9751789
    Abstract: The invention is directed towards methods and compositions for making and using fluorescent monomers which are synthesized by reacting a substituted or non-substituted benzoxanthene anhydride with an amine and with a moiety containing a polymerizable group. Such monomers are useful for the preparation of tagged treatment polymers. Such tagged treatment polymers are useful as scale inhibitors in industrial water systems.
    Type: Grant
    Filed: December 28, 2012
    Date of Patent: September 5, 2017
    Assignee: ECOLAB USA INC.
    Inventors: Jeffery M Atkins, Barbara E. Moriarty, Paul J. Zinn
  • Patent number: 9233421
    Abstract: Disclosed is a method of manufacturing nano-sized metal wire having a length-to-diameter ratio of at least 50 by using an ionic liquid in a polyol reduction using a metal salt as a precursor.
    Type: Grant
    Filed: November 17, 2009
    Date of Patent: January 12, 2016
    Inventors: Kwang Suck Suh, Jong Eun Kim, Tae Young Kim, Won Jung Kim
  • Publication number: 20150126510
    Abstract: The present invention relates to the field of HIV-1 infections, and in particular provides novel compounds containing triazine rings and suitable spacers. The compounds according to this invention are very suitable for the prevention and/or treatment of HIV-1 infection and in particular show improved activity against NNRTI-resistant viruses of HIV-1.
    Type: Application
    Filed: March 18, 2013
    Publication date: May 7, 2015
    Applicants: Universiteit Antwerpen, Shakturana CV
    Inventors: Jan Heeres, Koen Augustyns, Pieter Van Der Veken, Jurgen Joossens, Venkatraj Muthusamy, Kevin Karel Florentina Arien, Guido Louis Emile Vanham, Paulus Lewi (deceased)
  • Publication number: 20150110742
    Abstract: The present invention relates to chimeric chemical compounds which are used to recruit antibodies to cancer cells, in particular, prostate cancer cells or metastasized prostate cancer cells. The compounds according to the present invention comprise an antibody binding terminus (ABT) moiety covalently bonded to a cell binding terminus (CBT) and Toll-like receptor agonist (TLR) through a linker and a multifunctional connector group or molecule.
    Type: Application
    Filed: May 1, 2013
    Publication date: April 23, 2015
    Applicant: Yale University
    Inventors: David Spiegel, Kelly Fitzgerald
  • Publication number: 20150080393
    Abstract: The present invention is directed to spirocyclic compounds which are inhibitors of tryptophan hydroxylase (TPH), particularly isoform 1 (TPH1), that are useful in the treatment of diseases or disorders associated with peripheral serotonin including, for example, gastrointestinal, cardiovascular, pulmonary, inflammatory, metabolic, and low bone mass diseases, as well as serotonin syndrome, and cancer.
    Type: Application
    Filed: September 5, 2014
    Publication date: March 19, 2015
    Inventors: Stéphane De Lombaert, Daniel R. Goldberg, Kenneth Brameld, Eric Brian Sjogren, Andrew Scribner
  • Publication number: 20150073103
    Abstract: Multifunctional melamine epoxy resins, methylols and amines are provided. Methods of making multifunctional melamine epoxy resins, methylols and amines are also provided.
    Type: Application
    Filed: November 19, 2014
    Publication date: March 12, 2015
    Inventor: Georgius Abidal ADAM
  • Publication number: 20150072894
    Abstract: The invention provides a novel class of cyanine dyes that are functionalized with sulfonic acid groups and a linker moiety that facilitates their conjugation to other species and substituent groups which increase the water-solubility, and optimize the optical properties of the dyes. Also provided are conjugates of the dyes, methods of using the dyes and their conjugates and kits including the dyes and their conjugates.
    Type: Application
    Filed: September 17, 2014
    Publication date: March 12, 2015
    Applicant: Pacific Biosciences of California, Inc.
    Inventors: Stephen YUE, Gene SHEN, Wei-Chuan (David) SUN
  • Publication number: 20150057395
    Abstract: Compounds consisting of an oligomer or a polymer of a 1,3,5-triazine derivative, having the general formula I: wherein: X is selected from: or X is a heterocyclic radical containing in the ring at least one nitrogen atom which radical is linked to the triazine ring through one of such nitrogen atoms, R2 is alkyl or cycloalkyl, R1 is a divalent radical of piperazine of the formula or R2 is a divalent radical according to the formula or R2 is a radical according to the formula Y n is an integer from 2 to 30, inclusive, m is an integer from 2 to 6, inclusive, p is an integer from 2 to 12, inclusive, and X1=OH, NH2 or X whereby X and X1 may be the same or different, and, X2=H or is a C1-C4 alkyl group, and a solvent-free process for the production of the compounds of Formula I as well as the use of the self-extinguishing oligomeric or polymeric compounds as flame retardants and light stabilizers in thermoplastic polymers such as polypropylene or regenerated cellulose or polyester.
    Type: Application
    Filed: October 31, 2014
    Publication date: February 26, 2015
    Inventor: Bansi Lal Kaul
  • Publication number: 20150048338
    Abstract: The compound represented by the following general formula is useful as a light-emitting material for an organic light-emitting device. Z1, Z2 and Z3 in the following general formula each independently represent a substituent.
    Type: Application
    Filed: March 7, 2013
    Publication date: February 19, 2015
    Inventors: Chihaya Adachi, Tetsuya Nakagawa, Jie Li
  • Publication number: 20150050659
    Abstract: Protected fluorescent reagent compounds and their methods of synthesis are provided. The compounds are useful in various fluorescence-based analytical methods, including the analysis of highly multiplexed optical reactions in large numbers at high densities, such as single molecule real time nucleic acid sequencing reactions. The compounds contain fluorescent dye elements, that allow the compounds to be detected with high sensitivity at desirable wavelengths, binding elements, that allow the compounds to be recognized specifically by target biomolecules, and protective shield elements, that decrease undesirable contacts between the fluorescent dye elements and the bound target biomolecules and that therefore decrease photodamage of the bound target biomolecules by the fluorescent dye elements.
    Type: Application
    Filed: August 5, 2014
    Publication date: February 19, 2015
    Inventors: Lubomir SEBO, Jeremiah HANES, Gene SHEN, Louis BROGLEY, Stephen YUE, Frank ZHENG, Yuri LAPIN, John LYLE, Honey OSUNA, Andrei FEDOROV
  • Publication number: 20150045365
    Abstract: The present invention provides a compound of Formula (I), or a pharmaceutical acceptable derivative, salt or prodrug thereof. Further provided is a method of treatment of cancer in a subject comprising administering to said subject an effective amount of a compound of Formula (I), or a pharmaceutical acceptable derivative, salt or prodrug thereof. Further provided is the use of a compound of Formula (I), or a pharmaceutical acceptable derivative, salt or prodrug thereof in the preparation of a medicament for the treatment of cancer. In addition, the present invention also provides a pharmaceutical composition comprising a compound of Formula (I), or a pharmaceutical acceptable derivative, salt or prodrug thereof.
    Type: Application
    Filed: August 6, 2014
    Publication date: February 12, 2015
    Inventors: Antony Wilks Burgess, Francesca Walker, Keith Geoffrey Watson, Helen Witchard, Guillaume Lessene
  • Patent number: 8952150
    Abstract: Disclosed are compounds for inhibiting prostaglandin transporter (PGT) activity, pharmaceuticals compositions including the compounds, and methods of treating subjects using the compounds.
    Type: Grant
    Filed: September 20, 2010
    Date of Patent: February 10, 2015
    Assignee: Albert Einstein College of Medicine of Yeshiva University
    Inventors: Victor L. Schuster, Yuling Chi, Andrew S. Wasmuth, Richard S. Pottorf, Gary L. Olson
  • Publication number: 20150031698
    Abstract: Novel s-triazine compounds are disclosed that have a formula represented by the following: L1, L2, L3, R1, R2, R3, R4, R5a, R5b, and R5c are as described herein. The compounds may be prepared as pharmaceutical compositions, and may be used for the prevention and treatment of a variety of conditions in mammals including humans, where microbial infection is either a direct cause or a related condition.
    Type: Application
    Filed: August 3, 2014
    Publication date: January 29, 2015
    Inventor: Neville Robert KALLENBACH
  • Publication number: 20150031879
    Abstract: The present invention relates to novel processes for the preparation of sterically hindered amine ethers by the transformation of a corresponding oxo-piperidin to a hydroxy or amino substituted sterically hindered amine ether and the preparation of a N-propoxy or N-propenoxy substituted sterically hindered amine and some novel compounds obtainable by these processes. The compounds made by these processes are particularly effective in the stabilization of polymer compositions against harmful effects of light, oxygen and/or heat and as flame-retardants for polymers.
    Type: Application
    Filed: October 14, 2014
    Publication date: January 29, 2015
    Applicant: BASF SE
    Inventors: Markus FREY, Valerie Rast, Francisco Martinez, Davide Alvisi
  • Publication number: 20150018328
    Abstract: Provided are compounds useful for treating cancer and methods of treating cancer comprising administering to a subject in need thereof a compound described herein.
    Type: Application
    Filed: July 11, 2014
    Publication date: January 15, 2015
    Applicant: AGIOS PHARMACEUTICALS, INC
    Inventors: Zenon D. Konteatis, Janeta Popovici-Muller, Jeremy Travins, Robert Zahler, Zhenwei Cai, Ding Zhou
  • Publication number: 20150017189
    Abstract: The invention provides methods for attaching drugs, dyes or radiolabels to bis-MTX. This method can be used to prepare bis-MTX analogs that can be used to deliver agents, such as nanoparticles, drugs, dyes or radiolabels, to cells.
    Type: Application
    Filed: January 18, 2013
    Publication date: January 15, 2015
    Inventors: Carston R. Wagner, Jae Chul Lee, Sidath C. Kumarapperuma
  • Patent number: 8912293
    Abstract: A resin composition is provided. The resin composition comprises: an epoxy resin; a hardener, which comprises a melamine compound of Formula I: wherein, R is the same with or different from each other and has the formula of R1 and R2 are individually selected from a group consisting of H, a halogen, a substituted or unsubstituted C1-C15 alkyl group, a substituted or unsubstituted C1-C15 aloxy group, a substituted or unsubstituted C3-C15 cycloalkyl group, a substituted or unsubstituted C6-C20 aryl group, a substituted or unsubstituted C6-C20 aryloxy group, a substituted or unsubstituted C1-C15 unsaturated hydrocarbyl group, a naphthol group, a phenanthrenol group, and a dicyclopentadiene group, with a proviso that R2 is not H; and m is 1 or 2, wherein the amount of the hardener is about 20 parts by weight to about 150 parts by weight per 100 parts by weight of the epoxy resin.
    Type: Grant
    Filed: September 22, 2011
    Date of Patent: December 16, 2014
    Assignee: Taiwan Union Technology Corporation
    Inventor: Hsin-Ho Wu
  • Patent number: 8895731
    Abstract: The invention relates to novel intermediates for the preparation of substituted triazines used in particular in the cosmetic, detergent, coating, plastics and textile industries. The invention also relates to the processes for preparation of said intermediates and for the conversion of the latter into final products.
    Type: Grant
    Filed: June 8, 2012
    Date of Patent: November 25, 2014
    Assignee: 3V Sigma S.p.A.
    Inventors: Francesco Maestri, Luca Bemporad, Ferruccio Berte′
  • Patent number: 8895647
    Abstract: The present invention relates to oxygen-substituted sterically hindered amines of the formulae I or II: (II), wherein, for example, F2, R3, R5, R6, R8, R9, R11, R12, R13, R14 are n-butyl; Z1 to Z10 are propoxy and R1, R4, R7, R10, R13 are 2,2,6,6-tetramethyl-1-propoxy-piperidin-4-yl. Compositions comprising compounds of formulae I or II and an organic material, which is susceptible to oxidative, thermal or light-induced degradation, are further disclosed. Optionally, further additives are contained.
    Type: Grant
    Filed: August 31, 2010
    Date of Patent: November 25, 2014
    Assignee: BASF SE
    Inventors: Edoardo Menozzi, Massimiliano Sala, Anna Bassi, Holger Hoppe, Björn Ludolph, Gérard Lips
  • Publication number: 20140336313
    Abstract: The present invention relates to oxygen-substituted sterically hindered amines of the formulae I or II: (II), wherein, for example, F2, R3, R5, R6, R8, R9, R11, R12, R13, R14 are n-butyl: Z1 to Z10 are propoxy and R1, R4, R7, R10, R13 are 2,2,6,6-tetramethyl-1-propoxy-piperidin-4-yl. Compositions comprising compounds of formulae I or II and an organic material, which is susceptible to oxidative, thermal or light-induced degradation, are further disclosed. Optionally, further additives are contained.
    Type: Application
    Filed: July 28, 2014
    Publication date: November 13, 2014
    Applicant: BASF SE
    Inventors: Edoardo MENOZZI, Massimiliano SALA, Anna BASSI, Holger HOPPE, Björn LUDOLPH, Gérard LIPS
  • Patent number: 8877924
    Abstract: The invention provides triazine compounds and methods of their use to modulate protein kinases and to treat diseases mediated by said protein kinases.
    Type: Grant
    Filed: June 8, 2010
    Date of Patent: November 4, 2014
    Assignee: NantBio Inc.
    Inventors: Chunlin Tao, Qinwei Wang, David Ho, Laxman Nallan, Tulay Polat, Xiaowen Sun, Neil Desai
  • Publication number: 20140323488
    Abstract: The present invention relates to novel compounds (I) containing two disubstituted triazine rings covalently linked by an organic linker, thereby creating dimers. These compounds show activity against the causative infective agents of infectious diseases such as African trypanosomiasis, Chagas disease, Leishmaniasis, Malaria and HIV. The invention further relates to the prevention and/or treatment of these diseases.
    Type: Application
    Filed: November 9, 2012
    Publication date: October 30, 2014
    Inventors: Venkatraj Muthusamy, Louis Maes, Jan Heeres, Koen Augustyns, Pieter Van Der Veken, Jurgen Joossens, Paulas Joannes Lewi
  • Patent number: 8835629
    Abstract: The present invention provides a compound of Formula (I), or a pharmaceutical acceptable derivative, salt or prodrug thereof. Further provided is a method of treatment of cancer in a subject comprising administering to said subject an effective amount of a compound of Formula (I), or a pharmaceutical acceptable derivative, salt or prodrug thereof. Further provided is the use of a compound of Formula (I), or a pharmaceutical acceptable derivative, salt or prodrug thereof in the preparation of a medicament for the treatment of cancer. In addition, the present invention also provides a pharmaceutical composition comprising a compound of Formula (I), or a pharmaceutical acceptable derivative, salt or prodrug thereof.
    Type: Grant
    Filed: October 27, 2011
    Date of Patent: September 16, 2014
    Assignee: The Walter and Eliza Hall Institute of Medical Research
    Inventors: Antony Wilks Burgess, Francesca Walker, Keith Geoffrey Watson, Helen Witchard
  • Publication number: 20140252280
    Abstract: The present invention relates to compounds of formula (I), a process for their production and their use in electronic devices, especially electroluminescent devices. When used as electron transport and/or host material for phosphorescent emitters in electroluminescent devices, the compounds of formula I may provide improved efficiency, stability, manufacturability, or spectral characteristics of electroluminescent devices.
    Type: Application
    Filed: November 7, 2012
    Publication date: September 11, 2014
    Applicant: BASF SE
    Inventors: Thomas Schaefer, Ute Heinemeyer, Nicolle Langer, Annemarie Wolleb, Christian Lennartz, Soichi Watanabe, Teresa Marina Figueira Duarte, Gerhard Wagenblast, Didier Bauer, Ingo Muenster, Christian Schildknecht, Heinz Wolleb
  • Publication number: 20140221646
    Abstract: The present invention relates to a compound of Formula I: or a pharmaceutically acceptable salt thereof, wherein the symbols are as defined in the specification; a pharmaceutical composition comprising the same; and a method for treating or preventing autoimmunity disease using the same.
    Type: Application
    Filed: February 12, 2014
    Publication date: August 7, 2014
    Applicant: JANUS BIOTHERAPEUTICS, INC.
    Inventors: Grayson B. LIPFORD, Charles M. ZEPP
  • Patent number: 8796449
    Abstract: Novel s-triazine compounds are disclosed that have a formula represented by the following: L1, L2, L3, R1, R2, R3, R4, R5a, R5b, and R5c are as described herein. The compounds may be prepared as pharmaceutical compositions, and may be used for the prevention and treatment of a variety of conditions in mammals including humans, where microbial infection is either a direct cause or a related condition.
    Type: Grant
    Filed: March 17, 2011
    Date of Patent: August 5, 2014
    Assignee: New York University
    Inventor: Neville Robert Kallenbach
  • Publication number: 20140212364
    Abstract: Disclosed are oligomeric compounds obtained by condensation of the compound of formula (I) with itself wherein R1 and R2 are C1-C22 alkyl, isoalkyl or cycloalkyl groups.
    Type: Application
    Filed: March 13, 2013
    Publication date: July 31, 2014
    Applicant: 3V SIGMA S.p.A.
    Inventors: Massimo Fabbi, Carlo Seccomandi, Luca Bemporad, Ivan Balestra
  • Publication number: 20140187772
    Abstract: This invention describes novel pyrazole compounds of formula III: wherein Z1, Z2, and Z3 are as described in the specification; Q is —S—, —O—, —N(R4)—, or —CH(R6)—; R1 is T-Ring D, wherein Ring D is a 5-7 membered monocyclic ring or 8-10 membered bicyclic ring selected from aryl, heteroaryl, heterocyclyl or carbocyclyl; and R2 and R2? are as described in the specification. The compounds are useful as protein kinase inhibitors, especially as inhibitors of Aurora-2 and GSK-3, for treating diseases such as cancer, diabetes and Alzheimer's disease.
    Type: Application
    Filed: December 24, 2013
    Publication date: July 3, 2014
    Inventors: David Bebbington, Jean-Damien Charrier, Julian Golec, Francoise Pierard
  • Publication number: 20140176653
    Abstract: There is provided a compound represented by formula (1): in formula (1), L represents a divalent to tetravalent linking group; D represents a residue obtained by removing 1 to 5 hydrogen atoms from a compound represented by formula (2); m represents an integer of 1 to 10, however, each L may be the same with or different from every other L; n represents an integer of 2 to 10, however, each D may be the same with or different from every other D; and in formula (2), each of R4 to R24 independently represents a hydrogen atom or a substituent, provided that formula (2) has at least one or more ionic hydrophilic groups.
    Type: Application
    Filed: February 28, 2014
    Publication date: June 26, 2014
    Applicant: FUJIFILM CORPORATION
    Inventors: Yoshihiko FUJIE, Keiichi TATEISHI, Clive Edwin FOSTER
  • Publication number: 20140170538
    Abstract: There is provided a compound represented by Formula (1), and a coloring composition including the compound: wherein, in Formula (1), R0 to R3 each independently represent a hydrogen atom or a substituent, and R0 and R1, R0 and L, or R1 and L may be combined with each other to form a ring, L represents a single bond or a divalent linking group, D represents a residue in which n hydrogen atoms are removed from a compound represented by Formula (2), n represents an integer of 1 or more, provided that when n represents an integer of 2 or more, a plurality of R0's to R3's and L's may be the same or different, the compound represented by Formula (1) has at least one ionic hydrophilic group, and in Formula (2), R4 to R24 each independently represent a hydrogen atom or a substituent.
    Type: Application
    Filed: February 25, 2014
    Publication date: June 19, 2014
    Applicant: FUJIFILM Corpoartion
    Inventor: Yoshihiko FUJIE
  • Patent number: 8754084
    Abstract: The invention provides compounds, compositions and methods for treating myotonic dystrophy. The compounds can selectively bind to CUG repeats in RNA, or to CTG repeats in DNA, and inhibit replication of the nucleic acids.
    Type: Grant
    Filed: March 27, 2013
    Date of Patent: June 17, 2014
    Assignee: The Board of Trustees of the University of Illinois
    Inventors: Steven C. Zimmerman, Chun-Ho Wong, Paul J. Hergenrother, Jessie Peh
  • Publication number: 20140155599
    Abstract: The invention relates to a process for the purification of a melamine condensation product, comprising the steps of a) making a diluted slurry of a reaction product mixture comprising the melamine condensation product in a solution of a base in water with a pH of at least 9, b) keeping the diluted slurry for a period of at least 1 hour, c) concentrating the diluted slurry, thereby obtaining a concentrated slurry and an eluent, and d) washing the concentrated slurry by diluting the concentrated slurry with aqueous liquid and repeating step c, wherein the washing is performed by counterflow washing wherein eluents of downstream concentration steps are used to wash the slurry in upstream concentration steps.
    Type: Application
    Filed: March 27, 2012
    Publication date: June 5, 2014
    Applicant: DSM IP ASSETS B.V.
    Inventors: Christiaan Johannes Cornelis Stoelwinder, Gerard Jan Kwant
  • Publication number: 20140155379
    Abstract: Compounds and methods in the fields of chemistry and medicine are disclosed. Some of the disclosed embodiments include compounds, compositions and methods of using heterocycle amines. Some of the disclosed embodiments include heterocycle amines useful to treat inflammatory disorders.
    Type: Application
    Filed: December 20, 2013
    Publication date: June 5, 2014
    Applicant: Ligand Pharmaceuticals Incorporated
    Inventors: Koc-Kan Ho, David Diller, Jeffrey J. Letourneau, Brian F. McGuinness, Andrew G. Cole, David Rosen, Cornelis A. van Oeveren, Jason C. Pickens, Lin Zhi, Yixing Shen, Bijan Pedram
  • Patent number: 8742003
    Abstract: The present invention relates to silylated amino resins, to processes for preparing them, to their use, and to coating compositions comprising them.
    Type: Grant
    Filed: July 13, 2012
    Date of Patent: June 3, 2014
    Assignee: BASF SE
    Inventors: Christina Haaf, Markus Hickl, Ruediger Stark, Horst Hintze-Bruening, Bernd Bruchmann, Dirk Schmelter, Thomas Gloege, Christine Roesch
  • Publication number: 20140142305
    Abstract: The instant invention relates to novel water soluble bis-(triazinylamino)-stilbene optical brightening agents, a process for their preparation and their use for whitening natural and synthetic materials.
    Type: Application
    Filed: April 17, 2012
    Publication date: May 22, 2014
    Applicant: CLARIANT INTERNATIONAL LTD
    Inventors: Cedric Klein, Frederic Reveaud, Andrew Clive Jackson, David Atkinson
  • Patent number: 8722674
    Abstract: Disclosed herein are a 1,3,5-triazine-2,4,6-triamine compound or a pharmaceutically acceptable salt thereof, a preparation method thereof, and a composition for preventing or treating metabolic syndromes, diabetes, or cancers with deletion of P53 gene, which comprises the same.
    Type: Grant
    Filed: August 28, 2008
    Date of Patent: May 13, 2014
    Assignee: Hanall Biopharma Co., Ltd.
    Inventors: Hyae Gyeong Cheon, Kwang-Rok Kim, Sang Dal Rhee, Won Hoon Jung, Jong-Cheol Lee, Sung Wuk Kim, Sung Soo Jun
  • Patent number: 8657947
    Abstract: The present invention relates to silylated amino resins, to processes for preparing them, to their use, and to coating compositions comprising them.
    Type: Grant
    Filed: September 10, 2012
    Date of Patent: February 25, 2014
    Assignee: BASF SE
    Inventors: Bastian Noller, Reinhold Schwalm, Christine Roesch, Thomas Breiner, Jean-Francois Stumbe, Christina Haaf
  • Publication number: 20140011923
    Abstract: Compounds consisting of an oligomer or a polymer of a 1,3,5-triazine derivative, having the general formula I: wherein: X is selected from: or X is a heterocyclic radical containing in the ring at least one nitrogen atom which radical is linked to the triazine ring through one of such nitrogen atoms, R2 is alkyl or cycloalkyl, R1 is a divalent radical of piperazine of the formula or R2 is a divalent radical according to the formula or R2 is a radical according to the formula Y n is an integer from 2 to 30, inclusive, m is an integer from 2 to 6, inclusive, p is an integer from 2 to 12, inclusive, and X1?OH, NH2 or X whereby X and X1 may be the same or different, and, X2?H or is a C1-C4 alkyl group, and a solvent-free process for the production of the compounds of Formula I as well as the use of the self-extinguishing oligomeric or polymeric compounds as flame retardants and light stabilizers in thermoplastic polymers such as polypropylene or regenerated cellulose or polyester.
    Type: Application
    Filed: September 9, 2013
    Publication date: January 9, 2014
    Applicant: MCA Technologies GmbH
    Inventor: Bansi Lal Kaul
  • Publication number: 20140005370
    Abstract: Disclosed herein is a compound having Formula I: or a salt thereof, in which R1, R2 and R3 are as defined herein. Also disclosed are processes to prepare compounds of Formula I and use of compounds of Formula I to prepare stable glassy phases.
    Type: Application
    Filed: December 14, 2012
    Publication date: January 2, 2014
    Applicant: Her Majesty the Queen in right of Canada as represented by the Minister of National Defence
    Inventor: Her Majesty the Queen in right of Canada as represented by the Minister of National Defence
  • Patent number: 8608907
    Abstract: A composition suitable for paper brightening, wherein the composition contains one or more specified fluorescent whitening agents with taurine groups. The composition is used for whitening paper, in particular at the wet-end, in the size press or by coating.
    Type: Grant
    Filed: June 10, 2009
    Date of Patent: December 17, 2013
    Assignee: Blankophor GmbH & Co. KG
    Inventors: Bernhard Hunke, Michael Kraemer, Andrei Tauber, Günter Klug
  • Publication number: 20130323777
    Abstract: A ligand design allows compact nanoparticle materials, such as quantum dots (QDs), with excellent colloidal stability over a wide range of pH and under high salt concentrations. Self-assembled biomolecular conjugates with QDs can be obtained which are stable in biological environments. Energy transfer with these ligands is maximized by minimizing distances between QDs/nanoparticles and donors/acceptors directly attached to the ligands or assembled on their surfaces.
    Type: Application
    Filed: July 16, 2013
    Publication date: December 5, 2013
    Applicant: Naval Research Laboratory
    Inventors: Igor L. Medintz, Kimihiro Susumu, Michael H. Stewart
  • Patent number: 8597803
    Abstract: A light emitting composition includes a light-emitting lumophore-functionalized nanoparticle, such as an organic-inorganic light-emitting lumophore-functionalized nanoparticle. A light emitting device includes an anode, a cathode, and a layer containing such a light-emitting composition. In an embodiment, the light emitting device can emit white light.
    Type: Grant
    Filed: May 9, 2012
    Date of Patent: December 3, 2013
    Assignee: Nitto Denko Corporation
    Inventors: Jesse Froehlich, Hyun Sik Chae, Amane Mochizuki, Sheng Li
  • Patent number: 8580786
    Abstract: The invention provides for Triazine derivatives and their use to modulate protein kinase activity in a variety of conditions and diseases.
    Type: Grant
    Filed: December 17, 2010
    Date of Patent: November 12, 2013
    Assignee: Nant Holdings IP, LLC
    Inventors: Neil P. Desai, Patrick Soon-Shiong, Chunlin Tao, Qinwei Wang
  • Publication number: 20130281347
    Abstract: Novel compounds based on diaminostilbene are provided. The compounds conform to the general structures The compounds are useful as optical brighteners. Compositions, such as laundry compositions, containing such compounds are also provided.
    Type: Application
    Filed: June 3, 2013
    Publication date: October 24, 2013
    Inventors: Robert L. Mahaffey, Eduardo Torres, Dominick J. Valenti, Patrick D. Moore, Leland G. Close
  • Publication number: 20130281692
    Abstract: The invention relates to novel intermediates for the preparation of substituted triazines used in particular in the cosmetic, detergent, coating, plastics and textile industries. The invention also relates to the processes for preparation of said intermediates and for the conversion of the latter into final products.
    Type: Application
    Filed: June 8, 2012
    Publication date: October 24, 2013
    Applicant: 3V SIGMA S.P.A.
    Inventors: Francesco Maestri, Luca Bemporad, Ferruccio Berte'
  • Publication number: 20130261119
    Abstract: The present invention provides a compound of Formula (I), or a pharmaceutical acceptable derivative, salt or pro-drug thereof. Further provided is a method of treatment of cancer in a subject comprising administering to said subject an effective amount of a compound of Formula (I), or a pharmaceutical acceptable derivative, salt or prodrug thereof. Further provided is the use of a compound of Formula (I), or a pharmaceutical acceptable derivative, salt or prodrug thereof in the preparation of a medicament for the treatment of cancer. In addition, the present invention also provides a pharmaceutical composition comprising a compound of Formula (I), or a pharmaceutical acceptable derivative, salt or prodrug thereof.
    Type: Application
    Filed: October 27, 2011
    Publication date: October 3, 2013
    Applicant: The Walter and Eliza Hall Institute of Medical Research
    Inventors: Antony Wilks Burgess, Francesca Walker, Keith Geoffrey Watson, Helen Witchard, Guillaume Lessene